STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and share sales in company stock. On January 2, 2026, she exercised stock options for 204 and 4,796 shares of common stock at an exercise price of $10.42 per share. These options relate to grants that vest monthly and one award that was fully vested as of March 1, 2025.

On the same date, she sold 2,405 shares at a weighted average price of $38.6995 and 2,595 shares at a weighted average price of $39.5689, in multiple trades within stated price ranges. After these transactions, she directly held 12,965 shares of common stock and 2,377 and 2,983 stock options. All trades were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.

Positive

  • None.

Negative

  • None.
Insider Bachrodt Amy
Role SVP, Finance
Sold 5,000 shs ($196K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 204 $0.00 --
Exercise Stock Option (Right to Buy) 4,796 $0.00 --
Exercise Common Stock 204 $10.42 $2K
Exercise Common Stock 4,796 $10.42 $50K
Sale Common Stock 2,405 $38.6995 $93K
Sale Common Stock 2,595 $39.5689 $103K
Holdings After Transaction: Stock Option (Right to Buy) — 2,377 shares (Direct); Common Stock — 13,169 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.99 per share, inclusive. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 1, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bachrodt Amy
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Finance
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 M(1) 204 A $10.42 13,169 D
Common Stock 01/02/2026 M(1) 4,796 A $10.42 17,965 D
Common Stock 01/02/2026 S(1) 2,405 D $38.6995(2) 15,560 D
Common Stock 01/02/2026 S(1) 2,595 D $39.5689(3) 12,965 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.42 01/02/2026 M(1) 204 (4) 10/26/2032 Common Stock 204 $0 2,377 D
Stock Option (Right to Buy) $10.42 01/02/2026 M(1) 4,796 (5) 03/03/2031 Common Stock 4,796 $0 2,983 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.99 per share, inclusive.
4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
5. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 1, 2025.
/s/ Courtney Phillips, as attorney-in-fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did MAZE SVP Amy Bachrodt report on January 2, 2026?

She reported exercising stock options for 204 and 4,796 Maze Therapeutics common shares at an exercise price of $10.42, and selling 2,405 shares at a weighted average of $38.6995 and 2,595 shares at a weighted average of $39.5689.

How many Maze Therapeutics (MAZE) shares does Amy Bachrodt own after these Form 4 transactions?

Following the reported transactions, Amy Bachrodt directly owned 12,965 shares of Maze Therapeutics common stock, plus stock options covering 2,377 and 2,983 shares.

Were the MAZE insider share sales by Amy Bachrodt under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Amy Bachrodt on September 29, 2025.

At what prices did MAZE SVP Amy Bachrodt sell Maze Therapeutics shares?

She sold 2,405 shares at a weighted average price of $38.6995 per share, from multiple trades between $38.15 and $39.14, and 2,595 shares at a weighted average of $39.5689, from trades between $39.15 and $39.99.

What are the key terms of the Maze Therapeutics stock options exercised by Amy Bachrodt?

The stock options had an exercise price of $10.42 per share. One grant vests as to 1/48th of the total award monthly beginning November 1, 2022, and another grant was fully vested with the award becoming fully vested on March 1, 2025.

What is Amy Bachrodt’s role at Maze Therapeutics (MAZE)?

According to the filing, Amy Bachrodt is an officer of Maze Therapeutics, serving as SVP, Finance, and is not listed as a director or 10% owner.